Mattox D E, Von Hoff D D, Balcerzak S P
Johns Hopkins Hospital, Baltimore, MD.
Invest New Drugs. 1990 Feb;8(1):105-7. doi: 10.1007/BF00216934.
Eighteen patients are evaluable for response in a Phase II trial of Mitoxantrone for advanced adenoid cystic carcinoma of the head and neck. One patient had a complete response; there were no partial responses. Twelve patients had stable disease for 3 or more months. There was no significant anti-tumor activity of Mitoxantrone in the group of patients with adenoid cystic carcinoma, all of whom were previously heavily treated with surgery, chemotherapy and/or radiation therapy.
在一项米托蒽醌治疗晚期头颈部腺样囊性癌的II期试验中，有18例患者可评估疗效。1例患者完全缓解；无部分缓解病例。12例患者病情稳定3个月或更长时间。在腺样囊性癌患者组中，米托蒽醌没有显著的抗肿瘤活性，所有患者此前均接受过手术、化疗和/或放疗的重度治疗。
